Hapvida Earns a “Buy” Rating: Goldman Sachs Sees Bright Future Amidst Operational Gains

Goldman Sachs has elevated its outlook on Hapvida (HAPV3), shifting its recommendation from “neutral” to “buy” and raising the target price from R$4.90 to R$5.70.

This optimistic revision follows Hapvida’s impressive first-quarter performance in 2024, showcasing significant improvements in profitability and cash flow.

The company’s stock reacted positively, opening up 0.45% at R$4.50, buoyed by unexpected gains in loss ratios, profitability, net additions, and cash flow.

Analysts are now emphasizing Hapvida‘s long-term market prospects over short-term earnings fluctuations, aiming to mitigate stock volatility.

Goldman Sachs also suggests a potential revaluation of Hapvida’s shares, driven by operational enhancements.

The stock is currently valued at a price-to-earnings (P/E) ratio of 12.7 for the end of 2025. The firm anticipates this figure could rise, reflecting the company’s robust financial health.

They’ve adjusted their cash loss ratio forecast for 2025 to 68.1% from 68.3%, acknowledging steady improvements in unit costs.

Additionally, they predict an adjusted EBITDA margin of 14.9% for the same year.

Moreover, Goldman has upgraded its projection for Hapvida’s adjusted net income in 2025 to R$2.148 billion—an 8% year-over-year increase.

Optimistic Outlook for Hapvida

The favorable adjustment is backed by a more optimistic operational outlook and stronger financial outcomes.

Quicker-than-expected deleveraging and working capital normalization are accelerating these improvements.

Goldman Sachs’ upgraded stance on Hapvida not only reflects confidence in the company’s strategic plans but also underscores the broader potential in Brazil‘s healthcare sector.

Hapvida has positioned itself well to leverage strategic expansions and operational enhancements, ensuring sustained growth and profitability.

In short, these opportunities on the horizon promise to bolster its position further.

Related coverage: Embraer's High-Flying Stock: What's Next After a Stellar Rise? · Economic Crosswinds: The Forces Shaping Brazil's Stock Market Downturn · Market Moves: How Fed Decisions Ripple Through to Brazil's Currency · Market Turbulence: Carlyle's Major Stock Sale Shakes Up Rede D’Or

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.